As you know, there was no control group in phase 2 and since the phase 2 and phase 3 trial design are different, nobody can calculate the expected outcome with certainty. The key was to keep patients on treatment long enough for it to work. No clinical trials are "slam dunks" nor "crap shoots". Such language trivializes the detailed planning, the regulatory scrutiny, and the good faith of the physicians and patients who participate. Vical's Phase 3 trial has been designed and conducted with scientific precision to confirm or refute the hypothesis: That Allovetin will provide significant patient benefit compared with chemotherapy. I'am excited by Allovectin's potential ! I will post no other response in the future.